COMPOUNDS EXHIBITING JAK-KINASE ACTIVITY (VERSIONS), METHOD OF TREATING JAK-KINASE MEDIATED DISEASES, METHOD OF INHIBITING JAK-KINASE ACTIVITY (VERSIONS), PHARMACEUTICAL COMPOSITION OF SAID COMPOUNDS Russian patent published in 2013 - IPC C07D239/48 C07D403/12 C07D405/12 C07D405/14 A61K31/506 A61P35/00 C07D417/12 C07D413/12 C07D401/12 A61K31/5377 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new compounds of general formula III which possess the properties of JAK pathway inhibitors and JAK-kinase inhibitors. In formula III: X is specified in a group consisting of C₁-C₁₀alkyl, amino, halogen, carboxyl, carboxylic acid ester, C₂alkynyl, substituted tri-C₁-C₆alkylsilyl; R represents hydrogen; the cycle A is specified in a group consisting of C₆aryl, bicycloheptene, five-and sis-member mono- or 10-member bicyclic heteroaryl including 1 to 3 heteroatoms specified in a group of heteroatoms, including N, O or S, and five- or six-member mono- or 10-member bicyclic heterocycle, including 1 to 2 heteroatoms specified in a group of heteroatoms, including N or O; p means 0, 1, 2 or 3; each of R² is independently specified in a group consisting of C₁-C₆alkyl, C₁-C₄alkyl substituted by 1 to 3 substitutes. The other substitute and radical values are specified in the patent claim.

EFFECT: compounds may be used in preparing a therapeutic agent for T-cell mediated autoimmune disease, for treating or preventing allograft rejection in a recipient, for treating or preventing a type IV hypersensitivity reactions, which includes administering the above agent containing the compound according to cl 1-11, in an amount effective to treat the autoimmune disease or the allograft rejection or the type IV hypersensitivity.

23 cl, 7 dwg, 12 tbl, 43 ex